Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulcerative Colitis
Clinical trial register · Italy

Ulcerative Colitis Trials in Italy, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6779 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:19 UTC
6779
Studies in scope
all four open statuses
4070
Recruiting now
open to new participants
1013
Lead sponsors
across recruiting studies
Top sites
Milan 21 Rozzano 17 Rome 15 Bologna 14 Roma 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company5 AbbVie5 Takeda4 Merck Sharp & Dohme LLC2 Sanofi2 Gilead Sciences2 Abivax S.A.2 Spyre Therapeutics, Inc.2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 Alfasigma S.p.A.2 Pfizer2 IRCCS San Raffaele1 Janssen Research & Development, LLC1 Istituto Clinico Humanitas1 IRCCS Ospedale San Raffaele1 AnaptysBio, Inc.1 IRCCS Policlinico S. Donato1 Genentech, Inc.1 Catholic University of the Sacred Heart1
Site location
Milan21 Rozzano17 Rome15 Bologna14 Roma12 Palermo7 Naples7 Negrar7 Rho7 Padova5 Brescia4 Florence4 Monserrato4 Catanzaro4 Legnano4 San Donato Milanese4 Pisa4 Castellana Grotte4 San Giovanni Rotondo3 Turin3 Pavia3 Modena2 Trieste2 Cagliari2 Messina2 Pescara2 Catania2 Alessandria2 Torino2 Bergamo2 Fano1 Gazzi - Messina1 Monza1 Verona1 San Donato1 San Donato Milanese (MI)1 Ancona1 Genova1 Bari1 Segrate1
All 40 locations
Target enrolment
to

Ulcerative Colitis trials in Italy

38 of 6779 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Development of the SC-IBD Self-Care Measurement Scale
NCT07494227Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Observational
275
Roma
2026-10-30
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Legnano, Negrar
2026-06-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Bologna
2026-03-24
Recruiting
Sanofi
Phase 3
751
Rome, Rozzano, Turin
2026-01-16
Recruiting
Eli Lilly and Company
Phase 2
252
Milan, Roma, Rozzano
2025-11-10
Recruiting
Takeda
Phase 3
70
Messina, Milan, Pescara, Roma
2025-10-27
Recruiting
Sanofi
Phase 3
980
Legnano, Milan
2025-10-08
Recruiting
Genentech, Inc.
Phase 2
224
Rome, Brescia, Milan, Pavia, Rho, Rozzano, San Donato Milanese (MI), Turin
2025-09-29
Recruiting
Alfasigma S.p.A.
Phase 3
80
Alessandria, Ancona, Milan, Naples, Rome, Trieste
2025-09-29
Recruiting
AbbVie
Phase 3
120
San Giovanni Rotondo, Naples, Rome, Trieste
2025-07-28
Recruiting
Eli Lilly and Company
Phase 3
350
Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
2025-06-26
Active, closed
AbbVie
Phase 3
573
Monserrato, Rozzano, Milan, Naples, Rome, Bologna, Padova, Palermo
2025-06-17
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Castellana Grotte, Pavia, Legnano, Rozzano, San Donato Milanese, Segrate, Turin, Bologna
2025-05-27
Recruiting
Catholic University of the Sacred Heart
Not applicable
20
Roma
2025-05-14
Recruiting
IRCCS Ospedale San Raffaele
Observational
35
Milan
2025-02-27
Recruiting
Estimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)
NCT07095634Ulcerative Colitis, Myocardial Infarction, Stroke, Ischemic Heart Disease
IRCCS Policlinico S. Donato
Observational
600
San Donato Milanese
2025-02-07
Recruiting
Takeda
Phase 3
70
Messina, Milan, Pescara, Rome
2025-01-22
Recruiting
IRCCS San Raffaele
Not applicable
50
Milan
2024-11-21
Active, closed
Eli Lilly and Company
Phase 2
143
Bologna, Brescia, Fano, Florence, Gazzi - Messina, Milan, Modena, Monserrato
2024-10-10
Not yet open
Istituto Clinico Humanitas
Observational
174
Rozzano
2024-07-31
Active, closed
Takeda
Phase 2
213
Bologna, Milan, Palermo, Rome, Rozzano
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Bologna, Cagliari, Catanzaro, Milan, Negrar, Padova, Palermo, Roma
2024-03-27
Active, closed
AbbVie
Phase 2
156
Monserrato, Rome, Negrar
2024-03-23
Active, closed
Gilead Sciences
Phase 2
176
Catanzaro, Milan, Roma, Rozzano
2023-12-05
Active, closed
AnaptysBio, Inc.
Phase 2
132
Bologna, Cagliari, Catania, Legnano, Milan, Pavia, Rozzano, San Donato
2023-12-04
Active, closed
AbbVie
Phase 3
122
Florence, Rome, Bologna
2023-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Monserrato, San Giovanni Rotondo, Rome, Milan, Rozzano, Rho, Naples, Palermo
2023-10-25
Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2
64
Rome
2023-09-23
Active, closed
Alfasigma S.p.A.
Observational
509
Bari, Milan, Pisa, Negrar, Palermo, Rozzano, Torino
2023-06-12
Recruiting
Takeda
Phase 3
240
Naples, Bologna, Rome, Monza, Florence, Padova
2023-05-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
San Giovanni Rotondo, Rho, Rozzano, San Donato Milanese, Negrar, Alessandria, Bologna, Brescia
2023-01-16
Active, closed
AbbVie
Observational
785
Castellana Grotte, Rozzano, Milan, Naples, Rome, Negrar, Palermo, Pisa
2022-08-15
Active, closed
Abivax S.A.
Phase 2
203
Roma, Rozzano, Verona
2021-12-03
Active, closed
Pfizer
Phase 3
118
Bergamo, Naples, Roma, Bologna
2021-08-12
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bergamo, Bologna, Florence, Milan, Roma, Rome
2021-05-26
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bologna, Milan, Negrar, Padova, Palermo, Rho, Roma, Rozzano
2019-09-26
Active, closed
Pfizer
Phase 3
896
Castellana Grotte, Catania, Catanzaro, Brescia, Milan, San Donato Milanese, Rho, Modena
2019-09-05
Active, closed
Eli Lilly and Company
Phase 3
1,058
Catanzaro, Genova, Pisa, Rho, Roma, Rome, Rozzano, Torino
2018-07-18
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-italy/condition/ulcerative-colitis

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,779 studies in total at the last sync on 10 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies listing the condition Ulcerative Colitis.

How many Ulcerative Colitis trials are recruiting in Italy?

18 of the 38 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulcerative Colitis), 38 studies
PhaseStudiesRecruitingShare
Phase 316942.1%
Phase 212431.6%
Observational6215.8%
Not applicable225.3%
Phase 1/2112.6%
Phase 2/3102.6%

Most active sponsors

Lead sponsors with the most studies (Ulcerative Colitis)
Lead sponsorStudiesRecruiting
AbbVie51
Eli Lilly and Company53
Takeda43
Abivax S.A.20
Alfasigma S.p.A.21
Fondazione Policlinico Universitario Agostino Gemelli IRCCS21
Gilead Sciences20
Merck Sharp & Dohme LLC21
Pfizer20
Sanofi22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.